Acute Promyelocytic Leukemia for Fellows

Ashwin Kishtagari, MBBS, MSCI

Division of Hematology/Oncology, Vanderbilt University Medical Center

2026-08-18

Overview

What is APL?

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia — about 5–8% of AML.

  • Defined by the translocation t(15;17)(q24;q21), creating the PML::RARA fusion gene
  • Once rapidly fatal, it is now one of the most curable hematologic malignancies
  • The turnaround came from targeting the fusion protein directly — not cytotoxic chemotherapy

A Medical Emergency

The coagulopathy

APL is a hematologic emergency — the danger is not the leukemia burden but the bleeding.

  • A severe coagulopathy combining DIC and hyperfibrinolysis
  • Hemorrhage (intracranial, pulmonary) is the leading cause of early death
  • Early death remains the biggest threat to cure, especially in older patients

Warning

Catastrophic bleeding can occur in the first hours to days — before, and even during, effective treatment.

Act immediately

Suspected APL is treated before genetic confirmation returns.

  • Start ATRA at the first suspicion — do not wait for PCR/cytogenetics
  • Aggressive supportive care: transfuse platelets and replace fibrinogen / correct coagulopathy; hold invasive procedures
  • Confirm the diagnosis in parallel

Pathophysiology

PML::RARA blocks differentiation

The fusion protein is the engine of the disease.

  • RARA normally drives myeloid differentiation in response to retinoic acid
  • PML::RARA acts as an aberrant receptor that represses differentiation
  • Cells arrest at the promyelocyte stage and accumulate

How ATRA and ATO work

Two agents hit the same fusion protein at different ends — and act in synergy.

  • ATRA (all-trans retinoic acid) binds the RARA moiety → releases the block and drives differentiation of the leukemic promyelocytes
  • ATO (arsenic trioxide) binds the PML moiety → triggers degradation of PML::RARA and apoptosis

Together they clear the clone at both the differentiation and survival level — the basis of the modern chemo-free cure.

Diagnosis

Recognize, then confirm

Morphology / smear

  • Hypergranular promyelocytes, bundles of Auer rods (faggot cells)
  • Coagulopathy on labs (low fibrinogen, high D-dimer, thrombocytopenia)

Confirm PML::RARA

  • RT-PCR, FISH, or karyotype for t(15;17)
  • Rapid methods (FISH/PCR) support the presumptive diagnosis while treatment is already underway

Risk stratification (Sanz)

Risk is defined at presentation by white-cell and platelet counts (×10⁹/L):

Risk group WBC Platelets
Low ≤ 10 > 40
Intermediate ≤ 10 ≤ 40
High > 10 any

Low and intermediate risk are grouped as “non–high-risk” — the population where chemo-free ATRA + ATO is standard.

Treatment

The paradigm: ATRA + ATO

For non–high-risk APL, the standard of care is ATRA plus arsenic trioxide — no chemotherapy, no maintenance.

  • ATRA 45 mg/m²/day (divided) + ATO 0.15 mg/kg/day IV
  • Induction continues to hematologic remission; consolidation with the same agents
  • Established by the APL0406 (Lo-Coco et al., NEJM 2013) trial

APL0406 — practice-changing

APL0406 compared ATRA + ATO against standard ATRA + chemotherapy (AIDA) in non–high-risk APL.

Figure 1

Note

ATRA + ATO was non-inferior and in fact superior. R / ggplot2.

Durable cure

The advantage held up long-term — with strikingly few relapses.

(0.0, 112.0)

Figure 2

Note

APL0406 long-term (~50-month) outcomes. Cumulative relapse 1.9% vs 13.9%. Python / matplotlib.

High-risk disease

High-risk APL (WBC > 10) needs more than ATRA + ATO alone.

  • Add chemotherapy — an anthracycline (e.g. idarubicin) — to the ATRA + ATO backbone
  • Or add gemtuzumab ozogamicin (as used in the UK AML17 trial)
  • Early cytoreduction and vigilant management of leukocytosis are important

Key complications

Differentiation syndrome (formerly retinoic acid syndrome)

  • Fever, dyspnea, pulmonary infiltrates, edema, hypotension
  • Prophylaxis (e.g. prednisone 0.5 mg/kg/day) and prompt corticosteroids for suspected cases

Arsenic toxicity

  • QTc prolongation → monitor ECG and electrolytes at least twice weekly
  • Leukocytosis, hepatotoxicity

Monitoring

Response and cure are tracked molecularly.

  • MRD by PML::RARA RT-qPCR, typically after consolidation
  • Molecular relapse can precede hematologic relapse — enabling pre-emptive therapy

Summary

Summary

  • APL is AML with t(15;17) / PML::RARA — a bleeding emergency: start ATRA on suspicion and support aggressively
  • ATRA and ATO target the fusion at both ends — the basis of a chemo-free cure
  • Non–high-risk: ATRA + ATO is the standard (APL0406 — superior, durable, low relapse)
  • High-risk: add anthracycline or gemtuzumab ozogamicin
  • Watch for differentiation syndrome and QTc prolongation; monitor MRD by PCR

Warning

Educational overview built from well-established biology and published trial data (APL0406; ELN recommendations). Verify regimens, dosing, risk cut-offs, and monitoring against current authoritative guidelines and prescribing information before any teaching or clinical use.